Vincere Biosciences Secures $5 Million MJFF Grant to Advance First-in-Class Parkinson's USP30 Inhibitor to Clinical Trials
Key Insights
Vincere Biosciences (search) received a $5 million grant from The Michael J. Fox Foundation (search) to advance its lead USP30 inhibitor through IND-enabling studies toward 2026 clinical trials.
The company's first-in-class therapeutic targets mitochondrial dysfunction by selectively inhibiting USP30, a deubiquitinating enzyme that negatively regulates mitophagy in Parkinson's disease (search).
The funding will support pharmacology, toxicology, and regulatory studies required for FDA submission, along with biomarker development to measure target engagement.
Vincere Biosciences (search) has secured a $5 million grant from The Michael J. Fox Foundation (search) for Parkinson's Research to advance its lead USP30 inhibitor through critical IND-enabling studies toward Phase 1 clinical trials in 2026. The funding, awarded through MJFF's Therapeutics Pipeline Program, supports the development of what could be the first-in-class therapeutic targeting mitochondrial dysfunction in Parkinson's disease (search).
The grant will fund essential pharmacology, toxicology, and regulatory workstreams required for a successful Investigational New Drug (IND) application with the U.S. Food and Drug Administration. Additionally, the funding supports biomarker development efforts to evaluate target engagement and guide clinical translation, establishing a foundation for future human studies.
Targeting Mitochondrial Dysfunction at Disease Root
Vincere's approach addresses mitochondrial dysfunction and impaired mitophagy, which are central features of Parkinson's disease (search) pathophysiology. Mitophagy, the selective recycling of damaged mitochondria, is essential for maintaining neuronal health. In Parkinson's disease, this process becomes compromised, leading to toxic buildup of defective mitochondria that accelerates neurodegeneration (search).
The company's therapeutic strategy involves selectively inhibiting USP30, a mitochondrial deubiquitinating enzyme that acts as a negative regulator of mitophagy. By targeting this cellular process, Vincere aims to restore mitochondrial quality control and prevent the progression of neuronal injury.
"Mitochondria sit at the crossroads of Parkinson's and aging (the biggest risk factor for Parkinson's), fix the mitochondria and you strike at the root of the disease," said Dr. Spring Behrouz, co-founder and CEO of Vincere. "MJFF's support helps us move that science from the lab to the clinic."
Building on Previous Foundation Support
This latest award builds on prior MJFF support provided to Vincere in 2019 and 2022, which advanced the company's preclinical research. The continued collaboration reflects growing confidence in the USP30 target, which was initially prioritized by Vincere's AI discovery platform in 2018.
"The Michael J. Fox Foundation (search) remains steadfast in our mission to accelerate the development of transformative treatments and, ultimately, a cure for Parkinson's disease (search)," said Jessica Tome Garcia, PhD, MJFF's lead scientific program manager. "Our collaboration with Vincere Biosciences (search) over the years has supported the advancement of research targeting mitochondrial dysfunction, a key driver of Parkinson's pathology. This next phase of work builds on that foundation and represents important progress toward disease-modifying therapies that could meaningfully improve patients' lives."
Strategic Positioning for Partnership
The new funding strengthens Vincere's position as the company continues partnership discussions with larger pharmaceutical organizations that could accelerate clinical development. Andy Lee, co-founder and CBO of Vincere, noted the growing enthusiasm for USP30 since its initial prioritization.
"It's been exciting to see growing enthusiasm for USP30 since our AI platform prioritized this target in 2018," Lee said. "The new support from MJFF positions the company well for ongoing partnering discussions with larger organizations who may accelerate clinical development of this promising approach."
Company Profile and Development Pipeline
Boston-based Vincere Biosciences (search) develops small-molecule therapeutics that improve mitochondrial repair and recycling to address neurodegeneration (search) and age-related conditions. The company's lead USP30 inhibitor is an oral, brain-penetrant development candidate designed to provide disease-modifying benefits to millions of patients with Parkinson's disease (search).
The company integrates AI-guided discovery with mechanistic validation to advance medicines aimed at underlying cellular causes of disease. With the new MJFF funding, Vincere is positioned to transition its program from preclinical development to clinical testing, marking a significant milestone in the development of potential disease-modifying therapies for Parkinson's disease (search).